Literature DB >> 24316459

Cytokine and chemokine patterns across 100 days after hematopoietic stem cell transplantation in children.

Joseph DiCarlo1, Rajni Agarwal-Hashmi2, Ami Shah3, Paul Kim4, Laila Craveiro2, Renna Killen5, Yael Rosenberg-Hasson6, Holden Maecker6.   

Abstract

We mapped the cytokine response to hematopoietic stem cell transplantation (HSCT) by assaying 51 cytokines and chemokines each week for 100 days in 51 children receiving allogeneic (n = 44) or autologous HSCT (n = 7). Assay values were reported as mean fluorescence intensity (MFI). Log transformation converted MFI to clinically relevant measures (ie, pg/mL). We searched for potential markers of transplant complications by using mixed treatment by subject analysis of variance. Global cytokine secretion in HSCT recipients was significantly lower than in concurrent control patients (n = 11). Coincident with the nadir in WBC count, the concentration of many cytokines declined further by the second and third week. All analytes (except monokine induced by gamma interferon [MIG]) subsequently rebounded by week 4 (coincident with engraftment and recovery of WBC count) but often still remained well below control levels. Concurrent with the collective nadir of multiple cytokines, monocyte chemoattractant protein 1 (MCP-1), growth-regulated oncogene alpha (GRO-a), and leptin surged during weeks 2 to 4. High levels of leptin persisted throughout the 100 post-transplant days. Also during weeks 2 to 4, hepatocyte growth factor (HGF) and IL-6 surged in children with complications but not in those without complications. The peak in HGF was more pronounced in veno-occlusive disease (VOD). HGF and IL-6 secretion rose at least 2 weeks before the clinical diagnosis of VOD or graft-versus-host disease (GVHD). From week 4 onward in all groups, the MFI of the cytokine resistin increased to 5 to 15 times above concurrent control. HGF has now emerged in 3 or more biomarker discovery efforts for GVHD (and in our population for VOD as well). HGF (with or without IL-6) should be investigated as a potential predictive biomarker of VOD or GVHD. Alternatively, the hyperinflammatory "signature" provided by a multicytokine assay may be predictive.
Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone marrow transplantation; Cytokines; Graft-versus-host disease; Hepatocyte growth factor; Veno-occlusive disease

Mesh:

Substances:

Year:  2013        PMID: 24316459      PMCID: PMC4157600          DOI: 10.1016/j.bbmt.2013.11.026

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  23 in total

1.  Circulating concentrations of α- and β-chemokines in neonatal sepsis.

Authors:  Antonia Manoura; Dimitrios Gourgiotis; Emmanouil Galanakis; Emmanouil Matalliotakis; Eleftheria Hatzidaki; Eftichia Korakaki; Emmanouil Saitakis; Antonios S Marmarinos; Christine Giannakopoulou
Journal:  Int J Infect Dis       Date:  2010-08-03       Impact factor: 3.623

2.  Correlation of XMAP and ELISA cytokine profiles; development and validation for immunotoxicological studies in vitro.

Authors:  Eleonora Codorean; Cornelia Nichita; Lucian Albulescu; Elena Răducan; Ionela Daniela Popescu; Alina Constantina Lonită; Radu Albulescu
Journal:  Roum Arch Microbiol Immunol       Date:  2010 Jan-Mar

3.  Plasma biomarkers of lower gastrointestinal and liver acute GVHD.

Authors:  Andrew C Harris; James L M Ferrara; Thomas M Braun; Ernst Holler; Takanori Teshima; John E Levine; Sung W Choi; Karin Landfried; Koichi Akashi; Mark Vander Lugt; Daniel R Couriel; Pavan Reddy; Sophie Paczesny
Journal:  Blood       Date:  2012-01-27       Impact factor: 22.113

4.  Evaluation of multiplex immunoassays, used for determination of adiponectin, resistin, leptin, and ghrelin from human blood samples, in comparison to ELISA assays.

Authors:  Britt-Marie Loo; Jukka Marniemi; Antti Jula
Journal:  Scand J Clin Lab Invest       Date:  2011-02-03       Impact factor: 1.713

Review 5.  An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome.

Authors:  Angela Panoskaltsis-Mortari; Matthias Griese; David K Madtes; John A Belperio; Imad Y Haddad; Rodney J Folz; Kenneth R Cooke
Journal:  Am J Respir Crit Care Med       Date:  2011-05-01       Impact factor: 21.405

6.  Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma.

Authors:  C A Pappa; G Tsirakis; P Kanellou; M Kaparou; M Stratinaki; A Xekalou; A Alegakis; A Boula; E N Stathopoulos; M G Alexandrakis
Journal:  Cytokine       Date:  2011-09-21       Impact factor: 3.861

7.  Intra-individual variability over time in serum cytokine levels among participants in the prostate, lung, colorectal, and ovarian cancer screening Trial.

Authors:  Jonathan N Hofmann; Kai Yu; Rachel K Bagni; Qing Lan; Nathaniel Rothman; Mark P Purdue
Journal:  Cytokine       Date:  2011-07-20       Impact factor: 3.861

8.  Circulating inflammation markers and risk of epithelial ovarian cancer.

Authors:  Tess V Clendenen; Eva Lundin; Anne Zeleniuch-Jacquotte; Karen L Koenig; Franco Berrino; Annekatrin Lukanova; Anna E Lokshin; Annika Idahl; Nina Ohlson; Goran Hallmans; Vittorio Krogh; Sabina Sieri; Paola Muti; Adele Marrangoni; Brian M Nolen; Mengling Liu; Roy E Shore; Alan A Arslan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-04-05       Impact factor: 4.254

9.  CXCL1 and its receptor, CXCR2, mediate murine sickle cell vaso-occlusion during hemolytic transfusion reactions.

Authors:  Jung-Eun Jang; Eldad A Hod; Steven L Spitalnik; Paul S Frenette
Journal:  J Clin Invest       Date:  2011-03-07       Impact factor: 14.808

10.  Plasma cytokine profiles in subjects with high-functioning autism spectrum disorders.

Authors:  Katsuaki Suzuki; Hideo Matsuzaki; Keiko Iwata; Yosuke Kameno; Chie Shimmura; Satomi Kawai; Yujiro Yoshihara; Tomoyasu Wakuda; Kiyokazu Takebayashi; Shu Takagai; Kaori Matsumoto; Kenji J Tsuchiya; Yasuhide Iwata; Kazuhiko Nakamura; Masatsugu Tsujii; Toshirou Sugiyama; Norio Mori
Journal:  PLoS One       Date:  2011-05-27       Impact factor: 3.240

View more
  19 in total

Review 1.  How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT.

Authors:  S Fuji; A Rovó; K Ohashi; M Griffith; H Einsele; M Kapp; M Mohty; N S Majhail; B G Engelhardt; A Tichelli; B N Savani
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

2.  Hematopoietic Stem Cell Transplantation in ADA2 Deficiency: Early Restoration of ADA2 Enzyme Activity and Disease Relapse upon Drop of Donor Chimerism.

Authors:  Giorgia Bucciol; Selket Delafontaine; Heidi Segers; Xavier Bossuyt; Michael S Hershfield; Leen Moens; Isabelle Meyts
Journal:  J Clin Immunol       Date:  2017-10-10       Impact factor: 8.317

3.  Stem cell transplantation impairs dendritic cell trafficking and herpesvirus immunity.

Authors:  Carol A Wilke; Mathew M Chadwick; Paul R Chan; Bethany B Moore; Xiaofeng Zhou
Journal:  JCI Insight       Date:  2019-09-19

4.  A Canine Model of Chronic Graft-versus-Host Disease.

Authors:  Scott S Graves; Andrew Rezvani; George Sale; Diane Stone; Maura Parker; Steven Rosinski; Michele Spector; Bruce Swearingen; Leslie Kean; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2016-12-21       Impact factor: 5.742

Review 5.  Venous thromboembolism in hematopoietic stem cell transplant recipients.

Authors:  S Chaturvedi; A Neff; A Nagler; U Savani; M Mohty; B N Savani
Journal:  Bone Marrow Transplant       Date:  2015-12-21       Impact factor: 5.483

6.  Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment.

Authors:  George B McDonald; Laura Tabellini; Barry E Storer; Richard L Lawler; Paul J Martin; John A Hansen
Journal:  Blood       Date:  2015-05-18       Impact factor: 22.113

7.  Risk model incorporating donor IL6 and IFNG genotype and gastrointestinal GVHD can discriminate patients at high risk of steroid refractory acute GVHD.

Authors:  N Alam; W Xu; E G Atenafu; J Uhm; M Seftel; V Gupta; J Kuruvilla; J H Lipton; H A Messner; D D H Kim
Journal:  Bone Marrow Transplant       Date:  2015-03-16       Impact factor: 5.483

8.  Prediction of acute GVHD and relapse by metabolic biomarkers after allogeneic hematopoietic stem cell transplantation.

Authors:  Xiaojin Wu; Yiyu Xie; Chang Wang; Yue Han; Xiebing Bao; Shoubao Ma; Ahmet Yilmaz; Bingyu Yang; Yuhan Ji; Jinge Xu; Hong Liu; Suning Chen; Jianying Zhang; Jianhua Yu; Depei Wu
Journal:  JCI Insight       Date:  2018-05-03

9.  The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis.

Authors:  Bernd Hartz; Rebecca Marsh; Kanchan Rao; Jan-Inge Henter; Michael Jordan; Lisa Filipovich; Peter Bader; Rita Beier; Birgit Burkhardt; Roland Meisel; Ansgar Schulz; Beate Winkler; Michael H Albert; Johann Greil; Gülsün Karasu; Wilhelm Woessmann; Selim Corbacioglu; Bernd Gruhn; Wolfgang Holter; Jörn-Sven Kühl; Peter Lang; Markus G Seidel; Paul Veys; Alexandra Löfstedt; Sandra Ammann; Stephan Ehl; Gritta Janka; Ingo Müller; Kai Lehmberg
Journal:  Blood       Date:  2016-04-20       Impact factor: 22.113

10.  The pulmonary metatranscriptome prior to pediatric HCT identifies post-HCT lung injury.

Authors:  Matt S Zinter; Caroline A Lindemans; Birgitta A Versluys; Madeline Y Mayday; Sara Sunshine; Gustavo Reyes; Marina Sirota; Anil Sapru; Michael A Matthay; Sandhya Kharbanda; Christopher C Dvorak; Jaap J Boelens; Joseph L DeRisi
Journal:  Blood       Date:  2021-03-25       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.